Yes thanks for that. In this link they state.....
Admedus' which just released interim data from their current P2. In their release, they state "Significantly, there was a 90% decrease in viral lesions and outbreaks in trial patients, in the monthly rate versus baseline. A total of 14 patients also received the booster. The average number of days HSV-2 was detected in patients was also reduced versus baseline."
I must be slow today because I can't lay my hands on the source of this quote. Sorry to have to ask.... anyone?
The asx release states 81% after 2 doses where's this link and the response is indicating 90% after 3.
BIT BORING, page-18
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.00 |
Change
0.000(0.00%) |
Mkt cap ! $253.6M | |||
| Open | High | Low | Value | Volume |
| $11.88 | $12.00 | $11.50 | $261.8K | 22.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 156 | $11.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.00 | 6045 | 3 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |